As a physician-psychiatrist, I have watched the rise of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) with genuine admiration. They are transforming metabolic health, reducing cardiovascular risk, and offering hope to patients who have struggled for decades. For many, these medications are lifesaving.
But alongside the excitement, I’m witnessing something rarely discussed: a change in personality and affect, especially at higher doses.
This pattern reminds me of the early days of SSRIs. When fluoxetine was introduced, it was hailed as a medication that could reduce neuroticism and even “improve personality.” Only later did we fully recognize the trade-offs: emotional blunting, loss of motivation, reduced libido, and a subtle flattening of the inner emotional landscape.
Today, with GLP-1s, I’m observing a similar phenomenon. Patients lose weight (often dramatically) but report feeling “less alive.” Many describe diminished desire, reduced spontaneity, and a quieting of the internal drive that motivates daily life. Some also experience muscle wasting, which contributes to fatigue and further reduces their sense of vitality. What begins as decreased appetite sometimes generalizes into decreased enthusiasm for socializing, intimacy, or creative pursuits.
Among younger patients with eating disorders, I see another trend: Many love GLP-1s because they say the constant “food noise” in their minds has finally stopped. While the relief is understandable, the total silencing of this internal signal is not always a positive development; it can reinforce avoidance patterns and deepen the psychological roots of disordered eating.
Meanwhile, physicians are increasingly repurposing GLP-1s for addictions, compulsive behaviors, and even mood disorders, often without long-term psychiatric data. A medication that dampens cravings can seem appealing, but a medication that dampens all desire may come at a cost.
The core issue is simple: GLP-1s are not psychologically neutral. They affect appetite for food, but also appetite for life, making them, in practice, psychotropic medications. This does not diminish their remarkable benefits. But breakthroughs require vigilance. We must monitor not only weight and metabolic markers, but also joy, motivation, and emotional well-being.
If the SSRI era taught us anything, it is that early enthusiasm must be matched with long-term honesty. GLP-1s are powerful tools. Our responsibility is to use them with balance, humility, and an awareness of the whole person, not just their weight.
Farid Sabet-Sharghi is a psychiatrist.
